ScreenerHero

HIK Hikma Pharmaceuticals PLC

LSE · GB · Healthcare · Drug Manufacturers - Specialty & Generic · hikma.com
1579.00GBp-0.06%Mkt Cap: 3.55B $P/E: 12.05

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. Th…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.30BUSDP/E 25.0
TAK
Takeda Pharmaceutical Company Limited
$56.90BUSD
TEVA
Teva Pharmaceutical Industries Limited
$46.26BUSDP/E 66.1
HLN
Haleon plc
$38.79BUSDP/E 18.0
ZTS
Zoetis Inc.
$29.51BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
UTHR
United Therapeutics Corporation
$23.01BUSDP/E 19.2
VTRS
Viatris Inc.
$20.24BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.14BUSDP/E 110.6
NBIX
Neurocrine Biosciences, Inc.
$14.66BUSDP/E 21.1
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.25BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.26BUSDP/E 28.0
KRK
Krka, d. d.
$8.59BUSDP/E 19.2
ALKS
Alkermes plc
$7.17BUSDP/E 112.5
AMRX
Amneal Pharmaceuticals, Inc.
$7.09BUSDP/E 41.5
HIMS
Hims & Hers Health, Inc.
$6.92BUSD
LNTH
Lantheus Holdings, Inc.
$6.54BUSDP/E 24.3
KNSA
Kiniksa Pharmaceuticals International, plc
$5.87BUSDP/E 77.1
APTX
Apotex Health Corp.
$5.17BUSD

Key Statistics

Company
Market Cap3.55B USD
Enterprise Value5.55B USD
Revenue (TTM)3.72B USD
Gross Profit1.57B USD
Net Income (TTM)436.96M USD
Revenue/Share15.64 GBp
Last Price1579.00 GBp
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees9.5K
CountryGB
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)12.05
P/E (Forward)8.39
PEG1.71
EV/EBITDA5.81
EV/Revenue1.49
P/S0.96
P/B1.80
EPS (TTM)1.31
EPS (Forward)1.88
52W Range
1187.0058% of range1865.00
52W High1865.00 GBp
52W Low1187.00 GBp
Profitability
Gross Margin43.03%
Oper. Margin23.49%
EBITDA Margin25.71%
Profit Margin12.00%
ROE15.50%
ROA7.09%
Growth
Revenue Growth4.20%
Earnings Growth-4.70%
Cash Flow & Leverage
Operating CF473.91M USD
CapEx (TTM)344.57M USD
FCF Margin0.42%
FCF Yield0.44%
Net Debt1.81B USD
Net Debt/EBITDA1.90
Balance Sheet
Debt/Equity0.62
Current Ratio1.98
Quick Ratio1.02
Book Value/Sh8.80 GBp
Cash/Share1.33 GBp
Dividends
Fwd Div Rate0.64 GBp
Trail. Div Rate0.86 GBp
Div. Yield4.07%
5Y Avg Yield2.78%
Payout Ratio47.32%
Ex-Div DateAug 13, 2026
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)2041.99 GBp
Upside (mean)+29.3%
Target Range1739.12 GBp – 2620.94 GBp
1739.12+29.3% to mean2620.94
# Analysts12
Ownership
Shares Out.206.97M
Float145.97M
Insiders32.39%
Institutions40.34%
Technical
SMA 501606.92 (-1.7%)
SMA 2001490.73 (+5.9%)
Beta0.66
S&P 52W Chg14.58%
Avg Vol (30d)500.15K
Avg Vol (10d)434.52K
Technical Indicators
RSI (14)47.2
MACD-1.4705
MACD Signal-0.8771
MACD Hist.-0.5934
BB Upper1645.77 GBp
BB Middle1579.90 GBp
BB Lower1514.03 GBp
BB Width8.34%
ATR (14)39.82 GBp
Vol Ratio (20d)0.54x